BioMarin Pharmaceutical Receives Buy Rating from Merrill Lynch (BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN)‘s stock had its “buy” rating reaffirmed by equities researchers at Merrill Lynch in a research report issued on Monday, American Banking News reports.
A number of other analysts have also recently weighed in on BMRN. Analysts at Zacks reiterated a “neutral” rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note to investors on Friday, September 6th. They now have a $74.00 price target on the stock. Separately, analysts at Canaccord Genuity set a $85.00 price target on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note to investors on Thursday, September 5th. They now have a “buy” rating on the stock.
Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $69.58.
BioMarin Pharmaceutical (NASDAQ:BMRN) traded up 3.72% on Monday, hitting $73.40. 2,137,000 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 52 week low of $36.28 and a 52 week high of $76.34. The stock’s 50-day moving average is $66.1 and its 200-day moving average is $62.93. The company’s market cap is $10.284 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, July 25th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.13. The company had revenue of $136.80 million for the quarter, compared to the consensus estimate of $134.33 million. During the same quarter in the prior year, the company posted ($0.27) earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. On average, analysts predict that BioMarin Pharmaceutical will post $-1.16 earnings per share for the current fiscal year.
In other BioMarin Pharmaceutical news, EVP Robert Baffi sold 20,000 shares of BioMarin Pharmaceutical stock on the open market in a transaction dated Monday, September 9th. The stock was sold at an average price of $73.00, for a total transaction of $1,460,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.